Junshi Bio drugs added to national reimbursement list

Shanghai Junshi Biosciences Co., Ltd. announced that two new indications for its product Toripalimab Injection (TUOYI) and Ongericimab Injection (JUNSHIDA) have been successfully added to Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2025). This inclusion will take effect on January 1, 2026.

All 12 approved indications for TUOYI in Chinese Mainland are now on the NRDL, making it the sole anti-PD-1 monoclonal antibody for renal cancer, triple-negative breast cancer, and melanoma on the list. JUNSHIDA's first-time inclusion marks it as the only domestic PCSK9-targeted drug for statin-intolerant patients in the new NRDL edition.

These inclusions highlight the National Healthcare Security Administration's recognition of the drugs' clinical value and novelty, reinforcing state support for innovative pharmaceutical research and development. The company anticipates these additions will enhance affordability, accessibility, and sales, positively impacting long-term development.